TimothyJosephVoorheesMD, MSCR

Hematologic Oncology

Assistant Professor of Internal Medicine - Clinical

Dr. Voorhees is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Timothy Voorhees is a hematologist based in Columbus, OH, with a subspecialty in hematologic oncology. He completed his medical education at Ohio State University College of Medicine in 2014 and finished his residency in internal medicine at Ohio State University Hospital in 2017. He has served as an Assistant Professor at Ohio State University Health System since 2021 and was previously a Clinical Instructor at UNC Faculty Physicians. His research experience includes a focus on lymphoma, with multiple publications in notable journals such as the American Journal of Hematology and Blood Advances. Dr. Voorhees also acts as a Sponsor-Investigator in clinical trials investigating treatments like Tafasitamab and Rituximab for Post-Transplant Lymphoproliferative Disorder and the prevention of Cytokine Release Syndrome in CD19 Positive Non-Hodgkin Lymphoma.

PubMed

Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma.
Swetha Kambhampati Thiruvengadam, Reid Merryman, Yan Wang, Charles Gaulin, Evandro Bezerra
American Journal of Hematology. 2025-02-01
Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis.
Amneet Bajwa, Qiuhong Zhao, Marcus Geer, Chenyu Lin, James Westholder
Blood Advances. 2025-01-14
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma.
Sayan Mullick Chowdhury, Subodh Bhatta, Timothy J Voorhees, Kaitlin Annunzio, David A Bond
Journal of Hematology & Oncology. 2025-01-05

Abstracts/Posters

Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis
Timothy J Voorhees, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents
Timothy J Voorhees, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
Timothy J Voorhees, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
High Risk Cytogenetic and Immunohistochemistry Findings in Monomorphic Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplant _ a Single Center ...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019